Searched for
SUBHANU SAXENA
Timothy Crew set to leave CiplaTimothy Crew was one of the last remaining members from team Subhanu Saxena, the former CEO of Cipla.- Cipla aims to reach $1bn India sales through tie-upsCipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...
- Cipla registers 43.8% fall in Q1 net profit; global CEO Subhanu Saxena resignsConsolidated sales stood at Rs 3,500 crore, compared with Rs 3,760 crore in the year-ago quarter. ET Now poll had estimated sales of Rs 8,3...
- Cipla names Samina Vaziralli as Executive Vice-ChairmanVaziralli, daughter of MK Hamied -- the company's non-executive VC - has been a part of the core leadership team since joining the Mumbai-b...
- Cipla appoints Kedar Upadhye as Global CFOUntil recently, Kedar was Vice President, Global Generics Finance and Head of Investor Relations in Dr Reddy's Laboratories, Cipla said in ...
- Cipla creates management council to drive transformationIndia's third largest drug maker Cipla has created a five member management council, led by CEO Subhanu Saxena as part of its transformatio...
- Expect to complete US acquisitions by begnining of next quarter: Subhanu Saxena, Cipla"We are very happy with our strong results this quarter and growth momentum has continued for the first half of the year."
- Cipla Ltd ropes in Umang Vohra as Global Chief Financial and Strategy OfficerCipla Ltd today appointed former head of Dr Reddy's North American business Umang Vohra as its Global Chief Financial and Strategy Officer.
- Cipla not keen on major M&As to expand footprint: CEO Subhanu SaxenaCipla has said it is not "compelled" to go in for major M&As, preferring instead a semi-inorganic route to expand its global footprint.
- Successor-in-waiting Kamil Hamied leaves Cipla to pursue his own interestsKamil Hamied has quit Cipla, surprising those who had expected him to take a leadership role at India’s third-largest drug company.
- Can co-invest with government in health: Cipla's Subhanu SaxenaOver the 2-year period with Subhanu Saxena at the helm, Cipla's revenues have grown by over 30% to nearly Rs 11,500 crore.
- Cipla shares end nearly 4% higher post agreement with Serum InstituteCipla's stock surged 3.23 per cent to settle at Rs 618.60 on the BSE. In intra-day, it climbed 4.13 per cent to Rs 624.
- Cipla Ltd to market Serum Institute's paediatric vaccines in EuropeCipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Cipla Medpro collaborates with Teva Pharma; stock gainsThe collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively sell Teva’s broad pharmaceutical product po...
- Pharma companies on a talent hunt to fill skills gapThe sector has slowed from its peak growth rate, the lure of expansion in the Rs 75,000-crore pharma market has kept companies looking for ...
- Cipla will prioritise African markets for growth: CEO Subhanu SaxenaCipla will prioritise emerging markets across the African continent in its growth plans, the company's CEO Subhanu Saxena has said.
- Cipla floats in-house venture capital firmCipla's new initiative comes at a time when the company is making bold moves in expanding its international business.
- Cipla will stay close to innovation: Subhanu SaxenaSubhanu comes to Cipla with a diverse work experience across sectors, companies and locations such as Europe, North America, Africa and Asi...
- Cipla completes the Medpro deal, buys 100% stake in the South African companyThe total consideration payable by Cipla is approximately $ 512 million or ZAR 4.5 billion.
Load More
